GRPEL2 and diabetes mellitus: Considering that AAV-targeted gene therapies have low immunogenicity and have been explored in many preclinical and clinical studies, AAV9-Grpel2 treatment to alleviate heart dysfunction might be further validated in diabetic patients, which could be beneficial and provide hope for patients with diabetes.